The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tumor microenvironments present significant barriers to penetration by antibodies and immunoconjugates. Tumor microenvironments, however, are difficult to study in vitro. Cells cultured as monolayers exhibit less resistance to therapy than those grown in vivo and an alternative research model more representative of the in vivo tumor is more desirable. SS1P is an immunotoxin composed of the Fv portion of a mesothelin-specific antibody fused to a bacterial toxin that is presently undergoing clinical trials in mesothelioma. METHODOLOGY/PRINCIPAL FINDINGS: Here, we examined how the tumor microenvironment affects the penetration and killing activity of SS1P in a new three-dimensional (3D) spheroid model cultured in vitro using the human mesothelioma cell line (NCI-H226) and two primary cell lines isolated from the ascites of malignant mesothelioma patients. Mesothelioma cells grown as monolayers or as spheroids expressed comparable levels of mesothelin; however, spheroids were at least 100 times less affected by SS1P. To understand this disparity in cytotoxicity, we made fluorescence-labeled SS1P molecules and used confocal microscopy to examine the time course of SS1P penetration within spheroids. The penetration was limited after 4 hours. Interestingly, we found a significant increase in the number of tight junctions in the core area of spheroids by electron microscopy. Expression of E-Cadherin, a protein involved in the assembly and sealing of tight junctions and highly expressed in malignant mesothelioma, was found significantly increased in spheroids as compared to monolayers. Moreover, we found that siRNA silencing and antibody inhibition targeting E-Cadherin could enhance SS1P immunotoxin therapy in vitro. CONCLUSION/SIGNIFICANCE: This work is one of the first to investigate immunotoxins in 3D tumor spheroids in vitro. This initial description of an in vitro tumor model may offer a simple and more representative model of in vivo tumors and will allow for further investigations of the microenvironmental effects on drug penetration and tumor cell killing. We believe that the methods developed here may apply to the studies of other tumor-targeting antibodies and immunoconjugates in vitro.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These features confer to spheroids a similar anticancer drug resistance profile [124,125] to that exhibited by real solid tumors.”
From The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors (2019) · cites this paper as [125]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
The third dimension bridges the gap between cell culture and live tissue
Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2236 · Cited by 2,817 · cited 1×
“In vitro multicellular cancer spheroids, therefore, have begun to bridge the complexity gap between monolayer cell culture and in vivo tumors and have become valuable models in the study of drug resistance [6].”
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805 · cited 1×
“Nevertheless, spheroids offer an advantage based on the ability to examine the distribution of drugs in the absence of complicating factors such as pharmacokinetics, which often differ between mice and humans [33].”
BackgroundJohnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
Johnson, J. I., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M., Schepartz, S., Kalyandrug, S., Christian, M., Arbuck, S., Hollingshead, M., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1796 · Cited by 856 · cited 1×
“resistance acquired by tumor cells may contribute to difficulties in translating promising findings from in vitro studies into therapy [5].”
BackgroundTransport of Molecules, Particles, and Cells in Solid Tumors
Jain, R. K. (1999) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.1.1.241 · Cited by 691 · cited 1×
“ies and immunoconjugates within tumor masses [1].”
Multicellular resistance: a paradigm for clinical resistance?
Desoize, B. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00086-x · Cited by 400 · cited 1×
“and may be explained by “multicellular resistance,” a mechanism for drug resistance attributed to cell-cell contacts, cell-matrix contacts, and the three-dimensional (3D) shape found in tissue”
BackgroundMesothelin targeted cancer immunotherapy
Hassan, R., & Ho, M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.08.028 · Cited by 340 · cited 6×
“Although the biological function of mesothelin remains unclear, mesothelin’s limited expression in normal tissue and high expression in various cancers make it an attractive candidate for immunotherapy [12].”
BackgroundInfluentialSelf-citationPark, C. C., Zhang, H., Pallavicini, M., Gray, J. W., Baehner, F., Park, C. J., & Bissell, M. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3071 · Cited by 326 · cited 1×
“. In fact, inhibition of integrins has been shown to enhance breast cancer therapy”
BackgroundDynamic analysis of hepatoma spheroid formation: roles of E-cadherin and β1-integrin
Lin, R.-Z., Chou, L.-F., Chien, C.-C. M., & Chang, H.-Y. (2006) · Cell and Tissue Research · doi:10.1007/s00441-005-0148-2 · Cited by 305 · cited 1×
“. Interestingly, we found that the inhibitory antibody sensitizes the spheroids to immunotoxin therapy if the antibody was added before the formation of spheroids but not after. In the present study, we showed how silencing E-Cadherin expression or blocking its adhesive function does not completely disrupt spheroids,…”
Result
Cited by
Spherical Cancer Models in Tumor Biology
Weiswald, L.-B., Bellet, D., & Dangles-Marie, V. (2015) · Neoplasia · doi:10.1016/j.neo.2014.12.004 · Cited by 1,141
Vinci, M., Gowan, S., Boxall, F., Patterson, L., Zimmermann, M., Court, W., Lomas, C., Mendiola, M., Hardisson, D., & Eccles, S. A. (2012) · BMC Biology · doi:10.1186/1741-7007-10-29 · Cited by 1,024
“Since then, several methods have been used to generate tumor spheroids: spontaneous aggregation [19,20], spinner flasks [21], rotary cell culture systems [3,22], poly-2-hydroxyethyl methacrylate (polyHema)-coated plates [23,24], hanging drops [25], liquid overlay on agar [26-28], low binding plates [29,30], gel/ matri…”
MethodThree-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research
Pinto, B., Henriques, A. C., Silva, P. M. A., & Bousbaa, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121186 · Cited by 440
Xenaki, K. T., Oliveira, S., & van Bergen en Henegouwen, P. M. P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01287 · Cited by 289
“Inhibition of the adherens junction protein E-cadherin (and therefore disruption of cell–cell junctions) resulted in improved penetration and cytotoxicity of an immu-notoxin used in a 3D cell culture system of tumor cells (28).”
Three-dimensional in vitro culture models in oncology research
Jubelin, C., Muñoz-Garcia, J., Griscom, L., Cochonneau, D., Ollivier, E., Heymann, M.-F., Vallette, F. M., Oliver, L., & Heymann, D. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00887-3 · Cited by 264
AlgiMatrix™ Based 3D Cell Culture System as an In-Vitro Tumor Model for Anticancer Studies
Godugu, C., Patel, A. R., Desai, U., Andey, T., Sams, A., & Singh, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053708 · Cited by 234
“increase in the number of tight junctions in the core area of spheroids and increased expression of E-Cadherin a protein involved in the assembly and sealing of tight junctions [33].”
BackgroundCosta, E. C., de Melo‐Diogo, D., Moreira, A. F., Carvalho, M. P., & Correia, I. J. (2018) · Biotechnology Journal · doi:10.1002/biot.201700417 · Cited by 224
Trujillo-de Santiago, G., Flores-Garza, B. G., Tavares-Negrete, J. A., Lara-Mayorga, I. M., González-Gamboa, I., Zhang, Y. S., Rojas-Martínez, A., Ortiz-López, R., & Álvarez, M. M. (2019) · Materials · doi:10.3390/ma12182945 · Cited by 184
“Adhesion can be prevented by coating the culture surface with agar [153], agarose [120,130,152,154], poly (2-hydroxyethyl methacrylate) (polyHEMA) [125], or tri-block co-polymers, such as Pluronic (F108) [26].”
BackgroundRapid Generation of In Vitro Multicellular Spheroids for the Study of Monoclonal Antibody Therapy
Phung, Y. T., Barbone, D., Broaddus, V. C., & Ho, M. (2011) · Journal of Cancer · doi:10.7150/jca.2.507 · Cited by 98
Self-citationWeldon, J. E., Xiang, L., Zhang, J., Beers, R., Walker, D. A., Onda, M., Hassan, R., & Pastan, I. H. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0336 · Cited by 93
Self-citationKim, H., Phung, Y., & Ho, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039556 · Cited by 68
“In collaboration with Broaddus, we used this method to study antibody therapy in mesothelioma spheroids [3].”
BackgroundMethodResultSelf-citationImpact of multicellular tumor spheroids as an in vivo-like tumor model on anticancer drug response
Gălățeanu, B., Hudiță, A., Negrei, C., Ion, R., Costache, M., Stan, M., Nikitovic, D., Hayes, A. W., Spandidos, D. A., Tsatsakis, A. M., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3467 · Cited by 65
“Since then, several methods have been used to obtain MCTSs: spontaneous aggregation (27,28), spinner flasks (29), rotary cell culture systems (17), poly‐2‐hydroxyethyl methacrylate (poly‐Hema)‐coated plates (30,31), hanging drops (32), liquid overlay on agar (33-35), low binding plates (36,37), gel/matrix-based cultur…”
MethodAdvances in Liver Cancer Antibody Therapies: A Focus on Glypican-3 and Mesothelin
Ho, M. (2011) · BioDrugs · doi:10.2165/11595360-000000000-00000 · Cited by 56
Self-citationMimicking Tumors: Toward More Predictive In Vitro Models for Peptide- and Protein-Conjugated Drugs
van den Brand, D., Massuger, L. F., Brock, R., & Verdurmen, W. P. R. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00699 · Cited by 48
Two-Dimensional vs. Three-Dimensional In Vitro Tumor Migration and Invasion Assays
Zimmermann, M., Box, C., & Eccles, S. A. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-311-4_15 · Cited by 44
The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models
Blanquart, C., Jaurand, M., & Jean, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00388 · Cited by 47
Magdeldin, T., López-Dávila, V., Villemant, C., Cameron, G. W. W., Drake, R. A. L., Cheema, U., & Loizidou, M. (2014) · Journal of Tissue Engineering · doi:10.1177/2041731414544183 · Cited by 47
Barbone, D., Cheung, P., Battula, S. K., Busacca, S., Gray, S. G., Longley, D. B., Bueno, R., Sugarbaker, D. J., Fennell, D. A., & Broaddus, V. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052753 · Cited by 38
Self-citationKasagi, Y., Harada, Y., Morodomi, Y., Iwai, T., Saito, S., Yoshida, K., Oki, E., Saeki, H., Ohgaki, K., Sugiyama, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1563 · Cited by 35
“Second, spheroid formation promptly induces antiapoptotic genes that might be involved in the mechanism of drug resistance (25).”
BackgroundHN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy
Xiang, X. M., Feng, M., Felder, M. A. R., Connor, J. P., Man, Y., Patankar, M. S., & Ho, M. (2011) · Journal of Cancer · doi:10.7150/jca.2.280 · Cited by 34
“Future studies utilizing in vitro tumor spheroid models [47] and in vivo mouse models [48] are necessary to validate HN125 as a potential therapeutic agent for cancer therapy.”
BackgroundSelf-citationCunniff, B., Newick, K., Nelson, K. J., Wozniak, A. N., Beuschel, S. L., Leavitt, B. J., Bhave, A. D., Butnor, K. J., Koenig, A., Chouchani, E. T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127310 · Cited by 37
Jackson, M. R., Ashton, M., Koessinger, A. L., Dick, C., Verheij, M., & Chalmers, A. J. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.11.029 · Cited by 25
“Since expression of Bcl-2 proteins is influenced by culture dimensionality (34), efficacy in 3D culture is a critical step in preclinical validation.”
BackgroundLópez-Dávila, V., Magdeldin, T., Welch, H., Dwek, M. V., Uchegbu, I. F., & Loizidou, M. (2016) · Nanomedicine · doi:10.2217/nnm.15.206 · Cited by 24
Ohno, Y., Shingyoku, S., Miyake, S., Tanaka, A., Fudesaka, S., Shimizu, Y., Yoshifuji, A., Yamawaki, Y., Yoshida, S., Tanaka, S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0405-y · Cited by 22
Sato, Y., Elbadawy, M., Suzuki, K., Tsunedomi, R., Nagano, H., Ishihara, Y., Yamamoto, H., Azakami, D., Uchide, T., Nabeta, R., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114651 · Cited by 23
Feng, M., Zhang, J., Anver, M. R., Hassan, R., & Ho, M. (2011) · Journal of Cancer · doi:10.7150/jca.2.123 · Cited by 20
“In a recent study, we examined how the tumor microenvironment affected the penetration and killing activity of SS1P in a three-dimensional (3D) spheroid model cultured in vitro using NCI-H226 and two primary cell lines isolated from the ascites of MM patients [26].”
MethodSelf-citationShi, H., Rath, E. M., Lin, R. C. Y., Sarun, K. H., Clarke, C. J., McCaughan, B. C., Ke, H., Linton, A., Lee, K. M. L., Klebe, S., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.973576 · Cited by 24
“The poly HEMA 3D model has previously been used to examine immunotoxin therapy of human mesothelioma in vitro (16).”
MethodTomé‐Amat, J., Ruiz‐de‐la‐Herrán, J., Martínez‐del‐Pozo, Á., Gavilanes, J. G., & Lacadena, J. (2014) · FEBS Journal · doi:10.1111/febs.13169 · Cited by 18
A catalogue of treatment and technologies for malignant pleural mesothelioma
Schunselaar, L. M., Quispel-Janssen, J. M. M. F., Neefjes, J., & Baas, P. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1162100 · Cited by 16
“the original tumor closely regarding histological and molecular features [14,71,78,79].”
BackgroundSpheroids of HER2-Positive Breast Adenocarcinoma for Studying Anticancer Immunotoxins In Vitro
Balalaeva, I. V., Соколова, Е. А., Puzhikhina, A. D., Brilkina, A. A., & Deyev, S. M. (2017) · Acta Naturae · doi:10.32607/20758251-2017-9-1-38-43 · Cited by 12
PDMS well platform for culturing millimeter‐size tumor spheroids
Ratnayaka, S. H., Hillburn, T. E., Forouzan, O., Shevkoplyas, S. S., & Khismatullin, D. B. (2013) · Biotechnology Progress · doi:10.1002/btpr.1764 · Cited by 13
“approaches, cell surface receptors were altered to allow less binding with surfaces and more binding between cells.(8) Others utilize non-adhesive surfaces(9) or porous scaffolds(10) to grow tumor cells into a desired three-dimensional shape.”
BackgroundGresseau, L., Roy, M.-È., Duhamel, S., & Annabi, B. (2022) · Cancers · doi:10.3390/cancers14235944 · Cited by 14
“The expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL was induced in neurospheres in accordance with previous reports [23,24].”
Current and future options for the diagnosis of malignant pleural effusion
Rodríguez‐Panadero, F., & Romero‐Romero, B. (2013) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2013.786038 · Cited by 8
2ndPEGS Annual Symposium on Antibodies for Cancer Therapy
Ho, M., Royston, I., & Beck, A. (2012) · mAbs · doi:10.4161/mabs.21521 · Cited by 7
“He showed that the downregulation of E-Cadherin by siRNA and an E-Cadherin-specific functional blocking antibody could sensitize cancer cells to anti-mesothelin immunotoxin killing.(31) Andre Lieber (University of Washington) discussed junction opener 1 (JO-1), which is a small, recombinant adenovirus serotype 3-deriv…”
BackgroundMethodSelf-citationRecent advances on cancer-on-chip models: Development of 3D tumors and tumor microenvironment
Moghimi, N., Hosseini, S. A., Poudineh, M., & Kohandel, M. (2022) · Bioprinting · doi:10.1016/j.bprint.2022.e00238 · Cited by 8
Suares, A., Tapia, C., & Pardo, V. G. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.10.004 · Cited by 6
3D Models of Mesothelioma in the Study of Mechanisms of Cell Survival
Broaddus, V. C., Follo, C., & Barbone, D. (2017) · Current cancer research · doi:10.1007/978-3-319-53560-9_11 · Cited by 4
Self-citationCalafato, G., Bortolotti, M., Polito, L., & Bolognesi, A. (2025) · Toxins · doi:10.3390/toxins17060308 · Cited by 3
“…reported a decrease in immunotoxin efficacy in different types of 3D models compared to ACs, meaning that the chemical structure and intra-tumor diffusion of ITs, as well as the type of tumor and the molecular target, could be additional factors influencing the IT response in 3D models [34,35].”
Validation of chemoresistance phenotypes in pleural mesothelioma across 2D, 3D, and in vivo models
Shi, H., Selvamani, S. P., Zelei, R., Zhuang, L., Wang, D., Johnson, B., Dharwal, V., Xu, D., Wang, Y., Rutland, T., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-38692-4 · Cited by 3
Akagi, S., Ando, H., Matsuo, C. N. A., Tajima, K., Takata, H., Matsushima, T., Kusano, T., & Ishida, T. (2025) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b24-00804 · Cited by 3
Cultures cellulaires en trois dimensions : applications à la biologie des cancers
Jubelin, C., Golias, M., Cochonneau, D., Muñoz-García, J., & Heymann, D. (2025) · Bulletin du Cancer · doi:10.1016/j.bulcan.2025.09.004 · Cited by 2
Autophagy in 3D In Vitro and Ex Vivo Cancer Models
Follo, C., Barbone, D., Richards, W. G., Bueno, R., & Broaddus, V. C. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-8873-0_31 · Cited by 5
Self-citationMovia, D., & Prina‐Mello, A. (2018) · InTech eBooks · doi:10.5772/intechopen.69447 · Cited by 2
“They can be grouped into four main methodological categories: (i) hanging drop [85, 119, 120]; (ii) cell culture on non-adherent surfaces that effectively inhibits cellular attachment, such as (poly-HEMA)-coated plates [121, 122], low-binding plates [123, 124], ultra-low attachment (ULA) plates [125] or micro-patterne…”
BackgroundLauand, C. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2016.tde-25022016-095442 · Cited by 2
Efficacy of organic nanocarriers in a 3D colorectal cancer in vitro model
Davila, V. L. (2015) · UCL Discovery (University College London)
Cho, W.-W., Park, W., Cho, D., & Yi, H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823536-2.00003-1
Blanquart, C., & Scherpereel, A. (2026) · Thorax · doi:10.1136/thorax-2025-223284 · Cited by 1
Etude des propriétés mécaniques intrinsèques d’un modèle de microtumeur in vitro
Guillaume, L. (2017) · theses.fr (ABES) · doi:10.70675/98eaf292zbc52z4451z8a14z84364523ff6b
Metadata
- Authors
- Xiang, X., Phung, Y., Feng, M., Nagashima, K., Zhang, J., Broaddus, V. C., Hassan, R., FitzGerald, D., & Ho, M.
- Affiliations
- National Institutes of Health (US)
- University of California, San Francisco (US)
- Corresponding author
- Ho, Mitchell
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-01-31
- Volume
- 6
- Issue
- 1
- Pages
- e14640
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3031536
- OpenAlex
- W1994540190
- Cited by
- 51
- References
- 37
- Citations by year
- 2026: 2 · 2025: 3 · 2023: 3 · 2022: 4 · 2020: 2 · 2019: 3 · 2018: 4 · 2017: 6 · 2016: 5 · 2015: 4 · 2014: 2 · 2013: 4 · 2012: 5
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, public-domain)
- Figshare (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services (HHSN26120080001E)
- Mesothelioma Applied Research Foundation
- National Institutes of Health (HHSN26120080001E)
- National Cancer Institute (HHSN26120080001E)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- malignant mesothelioma, mesothelin, tumor microenvironment, tumor spheroids, drug penetration, tight junctions, E-cadherin, immunoconjugates, siRNA knockdown
- MeSH terms
- Antibodies, Antibodies, Monoclonal, Immunotoxins, Humans, Kinetics, Mesothelioma, Microscopy, Electron, Tumor Cells, Cultured, Cadherins, Spheroids, Cellular, Cell Culture Techniques, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.